Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.46 |
| ▸ | NPC1 | O15118 | 7/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 7/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.38 |
| ▸ | RELA | Q04206 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10179953 | 0.90 | RAB9A (0.47) | RAB9ANPC1PKMKMT2ALMNA | |
| SCHEMBL3766923 | 0.90 | PPARA (0.44) | RAB9ANPC1TP53S1PR1MAPT | |
| SCHEMBL3755883 | 0.87 | TP53 (0.58) | RAB9ANPC1PKMKMT2ATP53 | |
| SCHEMBL13765636 | 0.87 | TP53 (0.53) | RAB9ANPC1PKMKMT2ALMNA | |
| SCHEMBL3770756 | 0.83 | TP53 (0.59) | NPC1TP53S1PR1MAPT | |
| SCHEMBL3763187 | 0.83 | MAPT (0.49) | RAB9ANPC1PKMKMT2ALMNA | |
| SCHEMBL3761084 | 0.80 | NPC1 (0.54) | RAB9ANPC1PKMKMT2ALMNA | |
| SCHEMBL3755950 | 0.80 | MAPT (0.49) | RAB9ANPC1PKMKMT2ATP53 | |
| SCHEMBL3760886 | 0.80 | PPARA (0.45) | RAB9ANPC1TP53S1PR1MAPT | |
| SCHEMBL10179530 | 0.80 | TP53 (0.54) | RAB9ANPC1LMNATP53S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202856-B2 | Triazole oxadiazoles derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-8202856-B2 | Triazole oxadiazoles derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | OXA1L, RO60, PDCD11 | RAB9A 2114/4885NPC1 4730/4885PKM 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.